🎉 M&A multiples are live!
Check it out!

Akari Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Akari Therapeutics and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Akari Therapeutics Overview

About Akari Therapeutics

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).


Founded

2004

HQ

United States of America
Employees

12

Website

akaritx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$28.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Akari Therapeutics Financials

Akari Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Akari Therapeutics achieved revenue of n/a and an EBITDA of -$16.8M.

Akari Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Akari Therapeutics valuation multiples based on analyst estimates

Akari Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$23.1M -$16.8M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$17.4M -$17.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Akari Therapeutics Stock Performance

As of April 15, 2025, Akari Therapeutics's stock price is $1.

Akari Therapeutics has current market cap of $29.5M, and EV of $28.2M.

See Akari Therapeutics trading valuation data

Akari Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$28.2M $29.5M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Akari Therapeutics Valuation Multiples

As of April 15, 2025, Akari Therapeutics has market cap of $29.5M and EV of $28.2M.

Akari Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Akari Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Akari Therapeutics and 10K+ public comps

Akari Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $28.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.7x XXX XXX XXX
P/E -2.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Akari Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Akari Therapeutics Valuation Multiples

Akari Therapeutics's NTM/LTM revenue growth is n/a

Akari Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Akari Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Akari Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Akari Therapeutics and other 10K+ public comps

Akari Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -27% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Akari Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Akari Therapeutics M&A and Investment Activity

Akari Therapeutics acquired  XXX companies to date.

Last acquisition by Akari Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Akari Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Akari Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Akari Therapeutics

When was Akari Therapeutics founded? Akari Therapeutics was founded in 2004.
Where is Akari Therapeutics headquartered? Akari Therapeutics is headquartered in United States of America.
How many employees does Akari Therapeutics have? As of today, Akari Therapeutics has 12 employees.
Who is the CEO of Akari Therapeutics? Akari Therapeutics's CEO is Dr. Samir R. Patel, M.D..
Is Akari Therapeutics publicy listed? Yes, Akari Therapeutics is a public company listed on NAS.
What is the stock symbol of Akari Therapeutics? Akari Therapeutics trades under AKTX ticker.
When did Akari Therapeutics go public? Akari Therapeutics went public in 2012.
Who are competitors of Akari Therapeutics? Similar companies to Akari Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Akari Therapeutics? Akari Therapeutics's current market cap is $29.5M
Is Akari Therapeutics profitable? Yes, Akari Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.